EISAI’S ANTICANCER AGENT HALAVEN® NEWLY APPROVED IN JAPAN FOR TREATMENT OF SOFT TISSUE SARCOMA

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced on February 29 that it had received approval in Japan for its in-house developed anticancer agent Halaven® (eribulin mesylate) as a treatment of patients with soft tissue sarcoma. Halaven is the first and only single agent to demonstrate an overall survival (OS) benefit in a Phase III trial in patients with advanced, recurrent or metastatic soft tissue sarcoma (liposarcoma or leiomyosarcoma).